TRAF-1 Antibody (TRAF1/3298) [CoraFluor™ 1]

• Reactivity: Hu
• Applications: IHC, MA
• Clone: TRAF1/3298
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: CoraFluor 1

TRAF-1 Antibody (TRAF1/3298) [CoraFluor™ 1] Summary

• Description: CoraFluor(TM) 1 is a high performance terbium-based TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) or TRF (Time-Resolved Fluorescence) donor for high throughput assay development. CoraFluor(TM) 1 absorbs UV light at approximately 340 nm, and emits at approximately 490 nm, 545 nm, 585 nm and 620 nm. It is compatible with common acceptor dyes that absorb at the emission wavelengths of CoraFluor(TM) 1. CoraFluor(TM) 1 can be used for the development of robust and scalable TR-FRET binding assays such as target engagement, ternary complex, protein-protein interaction and protein quantification assays.
  
  CoraFluor(TM) 1, amine reactive
  
  CoraFluor(TM) 1, thiol reactive
  
  For more information, please see our CoraFluor(TM) TR-FRET technology flyer.
• Immunogen: Recombinant fragment of human TRAF-1 protein (around aa 73-219) (exact sequence is proprietary) (Uniprot: Q13077)
• Localization: Cytoplasmic
• Marker: Lymphomatoid Papulosis Marker
• Specificity: This monoclonal antibody recognizes a protein of 52kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30% of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84%) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7%). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.
• Isotype: IgG2b Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: TRAF1
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Immunohistochemistry-Paraffin
  • Protein Array
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark. Do not freeze.
• Buffer: PBS
• Preservative: No Preservative
• Purity: Protein A or G purified

Notes

CoraFluor (TM) is a trademark of Bio-Techne Corp. Sold for research purposes only under agreement from Massachusetts General Hospital. US patent 2022/0025254

Alternate Names for TRAF-1 Antibody (TRAF1/3298) [CoraFluor™ 1]

• EBI6
• EBI6MGC:10353
• Epstein-Bar virus-induced protein 6
• Epstein-Barr virus-induced protein 6
• TNF receptor-associated factor 1
• TRAF1
• TRAF-1

Background

The TRAF (TNF receptor-associated factor) family is a group of adapter proteins (TRAFs 1-6) that link a wide variety of cell surface receptors to diverse signaling cascades leading to the activation of NF-kB and mitogen-activated protein kinases (reviewed in Chung et al, 2002). TRAFs are major signal transducers for both the TNF and IL- 1/TLR receptor superfamilies and collectively play important functions in both adaptive and innate immunity. The carboxy-terminal region of TRAFs is required for self-association and interaction with receptor cytoplasmic domains following ligand-induced oligomerization. TRAFs interact with a variety of proteins that regulate receptor-induced cell death or survival, and TRAF-mediated signaling can promote cell survival or interfere with death receptor-induced apoptosis. This antibody recognizes TRAF1; human TRAF1 is a 416 amino acid protein.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: TRAF1